VX12-809-104 Lumacaftor + Ivacaftor in Cystic Fibrosis
Research type
Research Study
Full title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
IRAS ID
127851
Contact name
Jane Davies
Contact email
Sponsor organisation
Vertex Pharmaceuticals Incorporated
Eudract number
2012-003990-24
Clinicaltrials.gov Identifier
REC name
South Central - Berkshire Research Ethics Committee
REC reference
13/SC/0171
Date of REC Opinion
10 Jun 2013
REC opinion
Further Information Favourable Opinion